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Abstract: The release of cytokines by neutrophils constitutes an essential process in the development
of inflammation by recruiting and activating additional cells. Neutrophils are also able to secrete a
complex of S100A8 and S100A9 proteins (S100A8/A9), which can amplify the general inflammatory
state of the host and is involved in the pathogenesis of several chronic inflammatory diseases,
such as rheumatoid arthritis (RA). S100A8/A9 have received renewed attention due to their
susceptibility to several function-altering post-translational modifications. In that context, it has
been recently demonstrated that only the phosphorylated form of S100A8/A9 (S100A8/A9-P)
is able to induce the secretion of several cytokines in neutrophils. Here, we investigate the
mechanism by which this post-translational modification of S100A8/A9 can regulate the extracellular
activity of the protein complex and its impact on the inflammatory functions of neutrophils.
We found that S100A8/A9-P are present in large amounts in the synovial fluids from RA patients,
highlighting the importance of this form of S100A8/A9 complex in the inflammation process.
Using miRNA-sequencing on S100A8/A9-P-stimulated differentiated HL-60 cells, we identified a
dysregulation of miR-146a-5p and miR-155-5p expression through TRL4 signaling pathways. Our data
reveal that overexpression of these miRNAs in neutrophil-like cells reduces S100A8/A9-P-mediated
secretion of pro-inflammatory cytokines.
Keywords: miRNAs; cytokines; inflammation; S100A8/A9; neutrophils
1. Introduction
The most evident phenomenon concerning neutrophils is the remarkable evolution of the
researchers’ view of their role over the years. They have passed from the status of elementary cells
dedicated to pathogen killing to that of flexible and adaptive cells coordinating the immune response.
One of the critical elements to achieve such a determinant function is their ability to secrete a large
spectrum of cytokines, which recruit additional neutrophils and immune cells leading ultimately to an
amplification of the immune response [1–3].
Most cytokines originate from de novo synthesis, but preformed cytokines are also stored and
thus rapidly released upon appropriate stimulation [4,5]. This capacity of neutrophils to secrete a
specific cytokine profile depending on the underlining conditions [6] may determine their potential to
influence the development of inflammation and trigger pathological outcomes.
Neutrophils can also contribute to the perpetuation of the inflammatory process through the
secretion of S100A8 and S100A9, two EF-hand Ca2+-binding proteins, which have the ability to
form a protein complex (S100A8/A9, also called calprotectin). These proteins are now qualified
as damage-associated molecular pattern molecules (DAMPs) [7,8] due to their capacity to act as
cytokine-like proteins and possibility to recruit other cells and amplify the overall inflammatory
state. In this sense, S100A8/A9 have been described as being involved in the pathogenesis of chronic
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inflammatory diseases and more notably in rheumatoid arthritis (RA) [9–11]. Indeed, S100A8/A9 are
markedly up-regulated in the synovial fluid or serum of RA patients and can be used as sera-based
biomarkers to evaluate disease severity and progression [12,13].
The role of S100A8/A9 in disease development and progression is tightly related to their
pro-inflammatory activities [14,15]. The latter are primarily associated with the active heterodimer
form (S100A8/A9) [16], and recently, it has been established that the post-translational modification of
S100A9 is a critical event to regulate the DAMP functions of S100A8/A9 [17]. In this regard, based on
the use of DMSO-differentiated HL-60 cells (dHL-60), the phosphorylated form of S100A9 within the
S100A8/A9 complex (S100A8/A9-P) has recently been shown to induce the expression and secretion of
several cytokines. This event has been identified as mostly occurring through the activation of Toll-like
receptor 4 (TLR4) signaling pathways, although the involvement of other receptors cannot be excluded.
In fact, S100A8/A9-P could activate different types of receptors, which could allow the secretion of
different cytokine profiles. In that respect, TNFα, CCL3, CCL4, IL-6 and CXCL8 release appear to
be dependent on TLR4 signaling, whereas the release of CCL2 seems to be associated with a distinct
downstream signaling pathway activated by a distinct receptor [17]. The release of such cytokines by
neutrophils can participate in the dysregulation of the immune response and constitute a source of
severe tissue damage.
The implication of miRNAs, small non-coding RNAs of approximatively 20–22 nucleotides, as fine
regulators of gene expression in the modulation of neutrophil pro-inflammatory functions is only
beginning to emerge. In that context, overexpression of miRNA-451 has been associated with a decrease
of neutrophil chemotaxis through the inhibition of p38 MAPK phosphorylation and an attenuation of
arthritis severity [18]. To our knowledge, the impact of miRNAs on the regulation of cytokine secretion
by neutrophils has not yet been thoroughly investigated despite the importance of miRNAs and their
potential impact on cytokine secretion in the pathophysiology of autoimmune diseases.
In this study, we show that S100A8/A9-P are present in large amounts in synovial fluid from RA
patients, emphasizing the fact that this form is probably linked to the pro-inflammatory activities of
S100A8/A9 in this pathological context.
We investigate whether S100A8/A9-P are associated with alterations in the profile of miRNAs,
which may regulate cytokine secretion. Our data reveal that miR-146a and miR-155-5p are induced
by S100A8/A9-P stimulation in neutrophil-like HL-60 cells through activation of TLR4 signaling
pathways. For the first time, we provide evidence for an effect of these two miRNAs in the regulation
of S100A8/A9-P-induced cytokine secretion. Overexpression of miR-146a-5p and miR-155-5p using
miRNA mimics results in a decrease of cytokine secretion underlining the potential anti-inflammatory
role of these two miRNAs when upregulated.
Our study provides a novel insight in the importance of miRNAs in the regulation of crucial
pro-inflammatory neutrophil functions and shows their importance in ensuring the fine balance in the
inflammatory response in which neutrophils are involved.
2. Results
2.1. S100A9 Is Phosphorylated in Synovial Fluids from Rheumatoid Arthritis Patients
Recently, it was shown that neutrophil pro-inflammatory functions mediated by S100A8/A9
are tightly dependent on the phosphorylation state of S100A9 [17]. Although this post-translational
form of S100A9 could be a determinant player for the development of chronic and autoimmune
diseases, the presence of S100A8/A9-P in clinical samples has not yet been investigated to support
this assumption.
Because S100A8/A9 constitute a hallmark of RA and evidence has been provided for a role of
S100A8/A9 in RA pathogenesis, we determined whether S100A9-P was also present in the synovial
fluids of patients suffering from RA. For that, synovial fluids from RA patients were subjected to
western-blot analysis with a polyclonal antibody against phospho-specific S100A9. Synovial fluids
from osteoarthritis (OA) patients were used as control since OA is the result of excessive mechanical
stress on the joint and not an autoimmune disease like RA.
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In all synovial fluids from OA patients no S100A9-P was detected. This was also the case for total
S100A9 (including S100A9 and S100A8/A9-P) and S100A8 (Figure 1). In contrast, in almost two-thirds
of the synovial fluids from RA patients, a phosphorylated form of S100A9 was present (Figure 1). It is
important to note that in the synovial fluids in which S100A9-P were present, total S100A9 and S100A8
was also detected.
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Figure  1.  Presence  of  S100A8/A9‐P  in  synovial  fluids  from  rheumatoid  arthritis  (RA)  and 
osteoarthritis (OA) patients. 50 μg of proteins from synovial fluids from 14 RA and 14 OA patients 
were loaded on a 4–15% Tris‐Acetate gel for western blot analysis. S100A9‐P was detected with the 
anti‐S100A9‐P antibody  (custom‐made),  total S100A9 with  the B5 antibody and S100A8 using  the 
EPR3554 antibody. (L = ladder and positive control = leukopak purified S100A8/A9‐P). 
2.2. S100A8/A9‐P Induces the Expression of miRNA in Neutrophil‐Like Cells 
Recent findings showed that S100A8/A9‐P is able to induce the secretion of specific cytokines, 
contrary to S100A8/A9 [17]. We hypothesise that S100A8/A9‐P has an impact on cytokine expression 
and secretion by regulating the post‐transcriptional activity of miRNAs.   
In a first step, we performed miRNA‐sequencing experiments on dHL‐60 cells stimulated for 3, 
6  and  12  h with  10  μg/mL  S100A8/A9‐P. Volcano plots  (Figure  2A) were  created  to  graphically 
identify differentially expressed miRNA after stimulation with S100A8/A9‐P at different time points 
in dHL‐60 cells. In this aim, log2 fold change (FC) was plotted against the −log10 (p‐value) and only 
miRNA with a  log2 FC above 0.5 or below  −0.5 and a  false discovery  rate  (FDR) below 5% were 
considered. We found that only one miRNA was overexpressed 3 h after S100A8/A9‐P stimulation 
but the number of miRNAs differentially expressed increased with the time of stimulation (Figure 
2A).   
Because  volcano  plots  take  into  account miRNAs with  low‐abundance  expression, minimal 
changes  in miRNA  counts between non‐stimulated dHL‐60  cells and dHL‐60  cells  stimulated by 
S100A8/A9‐P can result in an overestimated FC. For this reason, MA plots were also established to 
graphically  visualize  the  difference  between  non‐stimulated  dHL‐60  cells  and  dHL‐60  cells 
stimulated by S100A8/A9‐P by including the average count per million (CPM) for both conditions. 
The MA plots (Figure 2B) showed that certain miRNAs with log2 FC above 0.5 or below 0.5 had a 
very  low average CPM value. miRNAs with an absolute difference of trimmed mean of M‐values 
(TMM, representing the normalized count of detected miRNA) between non‐stimulated dHL‐60 cells 
and dHL‐60 cells  stimulated by S100A8/A9‐P above 100, have been  identified as miRNAs whose 
Figure 1. Presence of S100A8/A9-P in synovial fluids from rheumatoid arthritis (RA) and osteoarthritis
(OA) patients. 50 µg of proteins from sy ovial fluids from 14 RA and 14 OA p tients were loaded on
a 4–15% Tris-Acetate gel for western blot analysis. S100A9-P was detected with the anti-S100A9-P
antibody (custom-made), total S100A9 with the B5 antibody and S100A8 using the EPR3554 antibody.
(L = ladder and positive control = leukopak purified S100A8/A9-P).
2.2. S100A8/A9-P Induces the Expression of miRNA in Neutrophil-Like Cells
Recent findings showed that S100A8/A9-P is able to induce the secretion of specific cytokines,
contrary to S100A8/A9 [17]. We hypothesise that S100A8/A9-P has an impact on cytokine expression
and secretion by regulating the post-transcriptional activity of miRNAs.
In a first step, we performed miRNA-sequencing experiments on dHL-60 cells stimulated for 3,
6 and 12 h with 10 µg/mL S100A8/A9-P. Volcano plots (Figure 2A) were created to graphically identify
differentially expressed miRNA after stimulation with S100A8/A9-P at different time points in dHL-60
cells. In this aim, log2 fold change (FC) was plotted against the −log10 (p-value) and only miRNA
with a log2 FC above 0.5 or below −0.5 and a false discovery rate (FDR) below 5% were considered.
We found that only one miRNA was overexpressed 3 h after S100A8/A9-P stimulation but the number
of miRNAs differentially expressed increased with the time of stimulation (Figure 2A).
Because volcano plots take into account miRNAs with low-abundance expression, minimal
changes in miRNA counts between non-stimulated dHL-60 cells and dHL-60 cells stimulated by
S100A8/A9-P can result in an overestimated FC. For this reason, MA plots were also established to
graphically visualize the difference between non-stimulated dHL-60 cells and dHL-60 cells stimulated
by S100A8/A9-P by including the average count per million (CPM) for both conditions. The MA plots
(Figure 2B) showed that certain miRNAs with log2 FC above 0.5 or below 0.5 had a very low average
CPM value. miRNAs with an absolute difference of trimmed mean of M-values (TMM, representing
th normaliz d count of det cted miRNA) between non-stimulated dHL-60 cells and dHL-60 cells
stimulated by S100A8/A9-P abov 100, have b en ident fied as miRNAs whose expression was altered
by S100A8/A9-P stimulation. In that context, while miR-146a-5p a d miR-146b-5p were found to be
overexpressed after 6 h of S100A8/A9-P stimulation, miR-155-5p expression was increased only after
12 h of stimulation.
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Figure 2. Effect of S100A8/A9-P on miRNA expression in dHL-60 cells. dHL-60 cells were stimulated
for 3, 6 and 12 h with 10 µg/mL S100A8/A9-P. (A) Volcano plot represents the log2 FC (fold change)
(x-axis) against the -log10 p-values (y-axis) for each miRNA identified using miRNA-sequencing.
(B) MA plot represents the average log CPM (count per million) value (x-axis) against the log2 FC
(y-axis) for each miRNA identified using miRNA-sequencing. From thr e ind pendent experiments,
criteria for an ffect of S100 8/A9-P on miRNA expression were defined as follows: FDR < 5%, log2
FC ≥ 0.5 and average trim d mean of (TMM) value difference between non-stimulat d dHL-60
cells and S100A8/A9-P stimulated dHL-60 cells ≥ 100. (C) dHL-60 cells were stimulated for 3, 6, 12,
18 and 24 h with 10 µg/mL S100A8/A9-P or S100A8/A9. The expression of miR-146a-5p and miR-155-5p
was assessed using qPCR. Data normalization was performed using three reference genes (RNUA1,
RNUA5, SCARNA17) and expressed as fold induction compared to the non-stimulated control (dashed
line). Results are presented as mean ± SEM of three independent experiments. * p < 0.05; ** p < 0.01;
*** p < 0.001; **** p < 0.0001.
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Since their biological importance has been related in the literature to the inflammation process
and associated to RA pathogenesis [19–24], miRNA-146a-5p and miR-155-5p have been selected
as potential important regulators of neutrophil inflammatory functions. The increased expression
of miRNA-146a-5p and miR-155-5p observed after RNA-sequencing and bioinformatics analyses
required validating. To this end, RT-qPCR was performed from RNAs of dHL-60 cells stimulated by
S100A8/A9-P for 3, 6, 12, 18 and 24 h. As expected, expression of miR-146a-5p and miR-155-5p in
dHL-60 cells was increased upon S100A9-P stimulation after 12 h of stimulation and continued to
increase up to 24 h (Figure 2C). Moreover, it was confirmed that non-phosphorylated S100A9 has no
effect on the expression of these two miRNAs.
2.3. S100A8/A9-P Induces miR-146a and miR-155 Expression through TLR4 Signaling Pathways
Since it had been demonstrated that cytokine secretion is mainly regulated through S100A8/A9-P /
TLR4 axis [17], we investigated whether the increase of miR-146a-5p and 155-5p expression observed
upon S100A8/A9-P stimulation was linked to TLR4 signaling pathway activation. For that purpose,
dHL-60 cells were treated with 1 µg/mL TLR4 neutralizing antibodies (or isotopic control, IgG,
see Figure S1) for 30 min, then stimulated with 10 µg/mL S100A8/A9-P for 18 h. Then, 1 µg/mL TLR4
neutralizing antibodies or isotypic control were added during the time of stimulation at 6 h and 12 h
in order to prevent the loss of TLR4 receptor blocking over time, which could result from antibody
degradation or internalization. miR-146a and miR-155 expression was quantified using RT-qPCR.
Blockade of TLR4 triggered a strong reduction of miR-146a-5p and 155-5p expression in the range
of 75–80% after S100A8/A9-P (Figure 3A,B) but did not completely abolish miRNA expression. This
could suggest that TLR4 is not fully inhibited and/or other signaling pathways independent of TLR4
are activated upon S100A8/A9-P stimulation. However, we can conclude that S100A8/A9-P effects are
primarily associated to TLR4 signaling pathways.
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Figure  3.  S100A8/A9‐P‐induced  miR‐146a  and  miR‐155‐5p  expression  through  TLR4  signaling 
pathway in dHL‐60 cells. dHL‐60 cells were incubated for 30 min with TLR4 neutralizing antibody, 
then stimulated with 10 μg/mL S100A8/A9‐P for 18 h. 1 μg/mL TLR4 neutralizing antibody was added 
at 6 h and 12 h of stimulation. Expression of (A) miR‐146a‐5p and (B) miR‐155‐5p were quantified 
using RT‐qPCR. Data normalization was performed using three reference genes (RNUA1, RNUA5, 
SCARNA17) and expressed as  fold  induction compared  to  the non‐stimulated control. Results are 
presented as mean ± SEM of three independent experiments. ** p < 0.01; **** p < 0.0001. 
2.4. miR‐146a‐5p and miR‐155‐5p Regulate Cytokine Secretion in dHL‐60 Cells 
2.4.1. Stable Expression of miRNA Mimics 
To  determine  the  impact  of  an  up‐regulation  of miR‐146a‐5p  and miR‐155‐5p  on  cytokine 
secretion, stable overexpression was performed through the transduction of viral vectors containing 
mimics  for miR‐146a‐5p  and miR‐155‐5p,  as well  as  a  non‐silencing  negative  control.  First, we 
identified the more effective promoter able to induce the expression of the different vectors using the 
SMARTchoice Promoter Selection Plate from Dharmacon. With a multiplicity of infection (MOI) of 
100, the mouse EF1 promoter (mEF1) was the most appropriate promoter regarding GFP expression 
and  signal  intensity  (Figure  4A).  Therefore,  different  vectors  were  designed  with  mEF1  and 
Figure 3. S100A8/A9-P-induced miR-146a nd miR-155- p expression through TLR4 signaling pathway
in dHL-60 cells. dHL-60 cells were incubated for 30 min with TLR4 neutralizing antibody, then
s imulated with 10 µg/mL S100A8/A9-P for 18 h. µ TLR4 neutral zing antibody was a ded
at 6 h and 12 h of sti . Expre sion of (A) miR-146a-5p and (B) miR-1 5-5p were quantified
using RT-qP . t lization was performed using thre referenc genes (RNUA1, RNUA5,
SCAR 17) a ex resse as fold induction compared to the non-stimulated control. Results are
presented as ean ± SE of three independent experiments. ** p < 0.01; **** p < 0.0001.
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2.4. miR-146a-5p and miR-155-5p Regulate Cytokine Secretion in dHL-60 Cells
2.4.1. Stable Expression of miRNA Mimics
To determine the impact of an up-regulation of miR-146a-5p and miR-155-5p on cytokine secretion,
stable overexpression was performed through the transduction of viral vectors containing mimics
for miR-146a-5p and miR-155-5p, as well as a non-silencing negative control. First, we identified the
more effective promoter able to induce the expression of the different vectors using the SMARTchoice
Promoter Selection Plate from Dharmacon. With a multiplicity of infection (MOI) of 100, the mouse EF1
promoter (mEF1) was the most appropriate promoter regarding GFP expression and signal intensity
(Figure 4A). Therefore, different vectors were designed with mEF1 and transduced into HL-60 cells
with a MOI of 100. The transduction efficiency was evaluated by the knockdown of the GAPDH
protein, which reached 80%, using a vector containing a shRNA directed against GAPDH (Figure 4B).
Finally, overexpression of miR146a-5p and miR-155-5p was validated using RT-qPCR in dHL-60 cells
and compared to the non-silencing negative control; the expression of both miRNAs were strongly
increased (Figure 4C,D). Taken together, these results clearly show that miR146a-5p and miR-155-5p
were successfully integrated into dHL-60 cells.
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Figure 4. Stable overexpression of miR‐146a and miR‐155‐5p by viral transduction in dHL‐60 cells. 
(A) GFP signal is visualized in dHL‐60 cells transduced with the GFP vector using the mouse EF1α 
promoter  (MOI  of  100)  with  the  SMARTchoice  Promoter  Selection  Plate  from  Dharmacon.  (B) 
Efficiency  of  GAPDH  knockdown  in HL‐60  cells,  transduced with  the  shRNA  directed  against 
GAPDH  was  analyzed  using  western  blot  (10%  Tris‐Tricine  gel).  Western  blot  results  are 
representative of three independent experiments. (C,D) Quantification of miR146a‐5p and miR‐155‐
5p  in  dHL‐60  transduced  with  both  miRNA  mimic  vectors  using  the  mEF1  promoter.  Data 
normalization  was  performed  using  three  reference  genes  (RNUA1,  RNUA5,  SCARNA17)  and 
expressed  as  fold  induction  compared  to  the  respective  transduced  negative  control. Results  are 
presented as mean ± SEM of six (for miR‐146a‐5) and three (for miR‐155‐5p) independent experiments. 
****p < 0.0001. 
2.4.2. Effect of miR146a‐5p and miR‐155‐5p Mimics on S100A8/A9‐P‐Induced Cytokine Secretion 
As previously mentioned, S100A8/A9‐P can only be obtained in limited quantities. In order to 
preserve the stock available for the next experiments, we validated the functionality of transduced 
dHL‐60 by stimulating them for 6 h with 100 ng/mL of LPS, which is well‐known to mediate its effects 
through  TLR4  signaling  pathways,  as we  observed  for  S100A8/A9‐P,  and  to  quantify  cytokine 
secretion, TNF‐α,  IL‐6, CCL2, CCL3, CXCL8,  IL‐12b  and CCL4 were  secreted by  cells upon LPS 
stimulation. Interestingly, the overexpression of miR146a‐5p and miR‐155‐5p mimics greatly reduced 
Figure 4. Stable overexpression of miR-146a and miR-155-5p by viral transduction in dHL-60 cells.
(A) GFP signal is visualized in dHL-60 cells transduced with the GFP vector using the mouse EF1α
promoter (MOI of 100) with the SMARTchoice Promoter Selection Plate from Dharmacon. (B) Efficiency
of GAPDH knockdown in HL-60 cells, transduced with the shRNA directed against GAPDH was
analyzed using western blot (10% Tris-Tricine gel). Western blot results are representative of three
inde endent experiments. (C,D) Quantificatio of miR146a-5p and miR-155-5p in dHL-60 transduced
with both miRNA mimic vectors using the mEF1 promoter. Data normalization was perfo med using
three reference gene (RNUA1, RNUA5, SCARNA17) and expressed as fold induction compared to the
respective transduced negative control. Results are presented as mea ± SEM f six (for miR-146a-5)
and three (for iR-155-5p) independent experiments. ****p < 0.0001.
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2.4.2. Effect of miR146a-5p and miR-155-5p Mimics on S100A8/A9-P-Induced Cytokine Secretion
As previously mentioned, S100A8/A9-P can only be obtained in limited quantities. In order to
preserve the stock available for the next experiments, we validated the functionality of transduced
dHL-60 by stimulating them for 6 h with 100 ng/mL of LPS, which is well-known to mediate its effects
through TLR4 signaling pathways, as we observed for S100A8/A9-P, and to quantify cytokine secretion,
TNF-α, IL-6, CCL2, CCL3, CXCL8, IL-12b and CCL4 were secreted by cells upon LPS stimulation.
Interestingly, the overexpression of miR146a-5p and miR-155-5p mimics greatly reduced the expression
of these cytokines compared to the negative control (Figure S2). Moreover, the putative mRNA targets
were determined according to Targetscan database predictions and literature with a special focus
on TLR4 signaling pathways [21,25]. The identified targets are TLR4, IRAK (1, 2 and 4), NF-kB1,
TAB2 and MyD88. Interestingly, overexpression of miR-146a-5p resulted in a reduction of all the
LPS-induced targets tested. In contrast, overexpression of miR-155-5p triggered only a decrease in the
LPS-induced expression of NF-κB1 and IRAK2 and a reduction tendency for LPS-induced TAB2 and
Myd88. These results clearly confirm that miR-146a-5p and miR-155-5p are involved in the regulation
of TLR4 signaling mediated by LPS in neutrophils by down-regulating the expression of key actors
(Figure S3).
Since transduced dHL-60 cells responded to LPS stimulation and mimics were efficient, dHL-60
cells were this time stimulated with 10 µg/mL S100A8/A9-P. Compared to LPS, only the secretion
of CCL2, CXCL8 and CCL4 was detected upon S100A8/A9-P cell stimulation (Figure 5). Secretion
of each of these cytokines was reduced by the overexpression of miR-146a-5p or miR-155-5p with a
more pronounced effect for miR-146a-5p. We can conclude from our results that miR-146a-5p and
miR-155-5p regulate S100A8/A9-P-mediated cytokine secretion.
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3. Discussion
Neutrophils secrete a broad spectrum of pro-inflammatory mediators in the extracellular
environment allowing them to exert a pivotal role by modulating immunity and the inflammatory
response. In that context, neutrophils are able to release S100A8/A9, which are considered as DAMPs
and found in large amounts in biological samples from patients with metabolic inflammatory diseases
(e.g., gout) and autoimmune diseases (e.g., rheumatoid arthritis, RA) [26–29]. Leukocyte recruitment
and induction of pro-inflammatory cytokine production are two major functions of DAMPs and
represent a feature of disease progression in which S100A8/A9 are involved by inducing inflammation.
In this sense, S100A8 and S100A9 have been described to induce cytokine secretion in phagocytes via
TLR4 signaling [30–32]. However, upon inflammatory conditions, in human neutrophils, S100A9 has
been reported to potentiate cytokine release rather than to directly stimulate their secretion [33]. In this
way, S100A9, but not S100A8, was found to act as a priming agent by amplifying CXCL8 secretion
induced by fMLF or GM-CSF. However, it is important to note that in this study, the effect of S100A8/A9
was not tested and recombinant S100A8 and S100A9 proteins were used, which were devoid of
post-translational modifications. Indeed, there is no doubt that the involvement of S100A8 and S100A9
in the regulation of inflammatory functions depends, among other things, on the monomeric and
oligomeric forms of S100A8 and S100A9 [34] as well as their post-translational modifications [35,36].
In support of this affirmation, it has been proposed that oxygen derivatives induce post-translational
modifications of S100A8/A9, through which the protein complex can scavenge released ROS and thus
limit the propagation of inflammation [37,38].
Besides the potential anti-inflammatory role of S100A8/A9, attributed to its oxidation state, the
pro-inflammatory effect of S100A8/A9 could be dependent on the phosphorylated state of S100A9.
Indeed, it has been recently described that S100A8/A9-P is able to induce cytokine secretion in dHL-60
cells in a TLR4-dependent manner [17]. However, how S100A8/A9-P can regulate such a determinant
function remains unknown and has never been investigated despite the importance that this form
of the complex could have in the pathogenesis of chronic inflammatory diseases. To reinforce this
assumption, our data provides evidence that S100A8/A9-P are found in large amounts in synovial
fluids from RA patients and are probably able to trigger the release of cytokines using neutrophils
present in the synovial fluid, thus amplifying the inflammatory state.
It is important to note that the phosphorylated form of S100A9 was present in two thirds of
synovial fluids from RA patients as well as total S100A9 and S100A8. Determination of the ratio
between phosphorylated and non-phosphorylated S100A8/A9 in those synovial fluids could potentially
be used as an additional predictive marker for a more precise assessment of disease progression.
Indeed, S100A8/A9 has been demonstrated to actively participate in RA pathogenesis [10,11,17,30].
Based on our previous results [17], we claim that phosphorylated S100A9 bears the pro-inflammatory
potential of S100A8/A9. In that context, the presence or absence of phosphorylated S100A9 in synovial
fluids from RA patients could be directly linked to the degree of RA progression. Indeed, the absence
of S100A8/A9-P in the samples could correspond to an early stage of the disease, while the presence
of S100A8/A9-P could mean that the disease is in a more advanced stage. To confirm or inform this
hypothesis, the amount of S100A8/A9-P needs to be attributed to the rheumatoid factor (for example)
and more samples need to be collected (at least 100) to be subjected to analysis. Moreover, all the
samples originated from treated patients and consequently the presence of S100A8/A9-P could be
dependent on the patients’ responsiveness to the therapy.
In the past few years, emphasis has been put on the study of miRNAs in the regulation of multiple
biological processes. Large advances have been made on the relationships between aberrant miRNA
expression and carcinogenesis, but their role in the development of autoimmune diseases remains
poorly understood. Because neutrophils are key cells associated with such types of diseases, an increase
of knowledge concerning the regulation of pro-inflammatory functions of neutrophils by miRNA may
be beneficial to define new strategies of therapy. Until now, the most evident impact of miRNA in the
regulation of neutrophil functions has been shown on the chemotaxis and concerned miRNA-451 [18].
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Here, we show that miRNA-146a and -155-5p are dysregulated upon S100A8/A9-P stimulation
and control cytokine secretion via TLR4 signaling pathways in a neutrophil-like model. The decrease or
stabilization of cytokine expression over time coincides with an increase of miR-146-5p and miR-155-5p
expression (Figure S4). These data support the assumption that these two miRNAs seem to be involved
in the negative feedback loop of cytokine expression.
Unfortunately, gene studies in primary neutrophils remain challenging, since they are always
non-genetically modifiable due to their status of terminally differentiated cells. An alternative consists
of using neutrophils from knock-out mice to study the mechanisms underlying neutrophil functions,
but we need to keep in mind that the profile of cytokine secretion in mice is different from that
in humans [39]. Moreover, in mice S100A9 is not phosphorylated due to a non-conserved Thr113
residue [40]. For these reasons, we decided to use the dHL-60 cell-like neutrophil model since these
cells have been used successfully to characterize the effect of gene/miRNA upregulation or knockdown
and it has been reported that neutrophils and dHL-60 cells show a similar profile of cytokine secretion
upon LPS stimulation [41]. Overexpression of miRNAs by lipofectamine-based mimic transfection
was ineffective in dHL-60 cells (data not shown). This could be explained by a defective incorporation
of the mimics into the RISC complex and thus the absence of repression of target mRNA. To overcome
this problem, stable overexpression of miR-146a-5p and miR-155-5p through viral transduction has
been realized. Moreover, overexpression of miR-146a-5p and miR-155-5p triggered a strong reduction
of LPS- and S100A8/A9-P-mediated CCL2, CCL4 and CXCL8 secretion.
Dysregulation of miR-146a-5p and miR-155-5p miRNAs have been shown to be linked to RA
pathogenesis and predominantly elevated in RA patients and arthritis models [19–24]. Moreover, it has
been pointed out that these two miRNAs can participate to the regulation of MyD88-dependent TLR
signaling and cytokine secretion in peripheral blood mononuclear cells and monocytes [42,43].
It is currently not clear whether miRNAs are promoting or inhibiting the RA progression [44]. In
macrophages from RA patients, miR-155 was shown to be upregulated and to promote the release of
IL-6 trough SHIP-1 inhibition [24].
According to our data, S100A8/A9-P, which is present in synovial fluids from RA patients, lead
to an increase of miR-146a and miR-155-5p through TLR4 signaling pathways. An overexpression
of these two miRNAs results in a sustained decrease of cytokine secretion induced by S100A8/A9-P.
Therefore, the control of miR-146a and miR-155-5p expression levels in neutrophils may offer a
promising anti-inflammatory option to reduce excessive inflammation in the context of chronic
inflammatory diseases.
4. Materials and Methods
4.1. Reagents and Antibodies
RPMI-1640, L-glutamine, penicillin and streptomycin were obtained from Life Technologies
(Gent, Belgium). Fetal bovine serum was purchased from Sigma-Aldrich (Bornem, Belgium). A BCA
Protein Assay kit was purchased from ThermoFischer Scientific, (Erembodegem, Belgium). If not
specifically mentioned, all the experiments were performed using physiological salt solution (PSS)
with the following composition: NaCl 115 mM, KCl 5 mM, KH2PO4 1 mM, D-Glucose 10 mM, MgSO4
1 mM, CaCl2 1.25 mM and HEPES-Na 25 mM, pH 7.4. Chemicals were of analytical grade and obtained
from Merck (Darmstadt, Germany).
4.2. Cell Culture
The human promyelocytic leukemia HL-60 cell line (ATTC, #CCL-240) was cultured in Roswell
Park Memorial Institute (RPMI) 1640 medium supplemented with 2 mM L-glutamine, 10% complement
heat-inactivated fetal bovine serum (FBS), 100 µg/mL streptomycin and 100 U/mL penicillin. Cells
were incubated at 37 ◦C, 5% CO2 and passaged every 3 days. HL-60 cells were differentiated into
dHL-60 by the addition of 1.3% v/v dimethylsulfoxide (DMSO) for 4.5 days [45].
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4.3. Collection of Synovial Fluids
Synovial fluids from RA and osteoarthritis (OA) patients were collected in collaboration with
LIMIDRA (Luxembourg Immune-Mediated Inflammatory Disease Research Association) and CHU
(Centre Hospitalier Universitaire) of Brest, France.
Synovial fluids from RA and OA patients were collected under written informed consent from all
participants, following the good clinical and ethical practices approved by the Ethics Review Panel
(ERP 17-005 NEUTRA, 14 June 2017) of the University of Luxembourg according to the guidelines of the
“Comité National d’Ethique de Recherche” (CNER 201701/07, 28 February 2017) and the “Commission
nationale pour la protection des données” (CNPD) from Luxembourg.
Synovial fluids were treated with 20 U/mL hyaluronidase (Carl Roth, Karlsruhe, Germany)
for 30 min at 37 ◦C. Then, synovial fluids were filtered through 100 µm cell-strainers (Greiner
Bio-One, Frickenhausen, Germany) centrifuged at 300 g for 15 min and treated with SigmaFast
protease/phosphatase inhibitor cocktail (Merck, Darmstadt, Germany). The synovial fluids acellularity
was checked using microscopy prior to determining the protein concentration using a Pierce 660
protein assay kit (Thermo Fisher Scientific, Erembodegem, Belgium). Finally samples were alicoted
and stored at −80 ◦C.
4.4. Western Blot of Synovial Fluids
50 µg of synovial fluid samples were centrifuged and loading buffer (Tris 200 mM, pH 8.8; SDS 2%;
Glycerol 10%; DTT 100 mM; β-mercaptoethanol 1%) was added before heating for 10 min at 96 ◦C. Then
samples were run on a Tris-Acetate gradient gel (4-15% acrylamide). Proteins were then either visualized
on gel using Coomassie blue staining or electrotransferred to a PVDF membrane (Merck-Millipore,
Overijse, Belgium). For the immunodetection of S100A9, mouse mAb B-5 (Santa Cruz, Heidelberg,
Germany) was used, while a custom-made rabbit pAb (Thermo Fisher Scientific, Erembodegem,
Belgium) was used to detect the phosphorylated form of S100A9. For the immunodetection of S100A8,
rabbit mAb EPR3554 (Abcam, Cambridge, UK) was used. Finally, anti-rabbit or anti-mouse coupled
with IRDye 800 CW or IRDye 680 (LI-COR Bioscience, Lincoln, NE, USA) were used as secondary
antibodies for fluorescent western blot detection using the Odyssey Infrared Imaging system (LI-COR
Biosciences, Lincoln, NE, USA).
4.5. Purification of S100A8/A9 and S100A8/A9-P
S100A8/A9 and S100A8/A9-P were purified from human granulocytes according to the method
published by van den Bos et al. [46] and already described [17]. Briefly, granulocytes were purified
from fifty human leukopaks, pooled together and lysed by sonication. The cytosolic fraction containing
the majority of S100A8 and S100A9 proteins were obtained by ultra-centrifugation (200,000 g for 1 h
at 4 ◦C). Total protein concentration of the cytosolic fractions was quantified with PIERCE 660 nm
Protein Assay (Thermo Fischer Scientific, Erembodegem, Belgium) and adjusted to 3 mg/mL using
buffer A solution (Tris 50 mM, EDTA 1 mM, EGTA 1 mM, dithiothreitol, 1 mM, pH 8.5). Because
S100 proteins are soluble in ammonium sulfate solutions, a substantial portion of unwanted proteins
were removed by 70% w/v ammonium sulfate precipitation for 2 h at 4 ◦C followed by centrifugation
at 10,000 g for 30 min at 4 ◦C. The S100A8/A9 enriched supernatants were retrieved and dialyzed
against buffer A overnight at 4 ◦C with a buffer refreshment of four times. In the final purification
step, S100A8/A9 and S100A8/A9-P were purified by FPLC using an anion exchange column (HiTrap Q
XL, GE Healthcare Life Sciences, Diegem, Belgium) and eluted with a gradient of NaCl 0–0.4 mM at
a flow rate of 1 mL/min. While pure S100A8/A9 was eluted at NaCl concentrations in the range of
0.12-0.135 mM, S100A8/A9-P was obtained using a NaCl concentration in the range of 0.25-0.27 mM.
Protein purity in each eluted fraction was determined using SDS-PAGE under reducing conditions
and visualized using Coomassie blue staining. Additionally, presence of a potential contamination
by S100A12 was determined by western blot [47]. Finally, S100A8/A9 or S100A8/A9-P fractions were
pooled and concentrated to a workable concentration using Amicon® Ultra 3K Centrifugal Filter Units
(Merck, Darmstadt, Germany). To exclude endotoxin contamination in the S100 preparations, a LAL
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Chromogenic Endotoxin Quantitation test (Pierce LAL Chromogenic Endotoxin Quantitation Kit,
Thermo Fisher Scientific, Erembodegem, Belgium) was performed. Since concentrations as low as 0.002
ng/mL and 0.003 ng/mL of LPS were found in the S100A8/A9 and S100A8/A9-P batches respectively,
we considered our preparations to be endotoxin-free.
4.6. RNA Extraction and Reverse Transcription
Total RNA from dHL-60 cells was extracted using a Quick-RNA Miniprep Kit (Zymo Research,
Irvine, CA, USA) and according to the manufacturer’s instructions. Reverse transcription of
mature miRNA was performed using 0.5 µg total RNA and the miScript II RT kit (Qiagen, Venlo,
The Netherlands) according to the manufacturer’s instructions.
4.7. miRNA Sequencing and Analysis
miRNA sequencing was performed using Exiqon (Vedbaek, Denmark). Next-generation
sequencing (NGS) libraries were prepared, quantified and sequenced using single-end reads with the
Illumina Nextseq 500 instrument. Quality control, alignment and downstream analysis was provided
by Exiqon.
4.8. Quantitative Real-Time PCR
qPCR was performed using primers for miR-146a-5p (Qiagen, MS00003535) and miR-155-5p
(Qiagen, MS00031486) as well as for reference genes RNU1A (Qiagen, MS00013986), RNU5A (Qiagen,
MS00013993) and SCARNA17 (Qiagen, MS00014014) with iTaqTM Universal SYBR Green Supermix
(Bio-Rad, Hercules, CA, USA) in a QuantStudio 12K Flex real-time PCR machine (Thermo Fischer
Scientific, Erembodegem, Belgium) using the following program: 2 min at 95 ◦C followed by 40 cycles
of 3 s at 95 ◦C and 20 s at 60 ◦C.
For cytokine RNA expression, the following primers were used: CCL2 (forward, 5′-CTGCTCATA
GCAGCCACCTT-3′; reverse, 5′-GCTTCTTTGGGACACTTGCT-3′), CCL4 (forward, 5′- CACCAATGG
GCTCAGAC-3′; reverse, 5′-GCTGCTGGTCTCATAGTAATC-3′), CXCL8 (forward, 5′- ACAAGAGCCA
GGAAGAAAC-3′; reverse, 5′-AACTGCACCTTCACACAG-3′), Actin (forward, 5′- GCCCTGAGGCA
CTCTTCCA-3′; reverse, 5′-TGTTGGCGTACAGGTCTTTGC-3′), B2M (forward, 5′- AAGCAGCATCAT
GGAGGTTT-3′; reverse, 5′-TGGAGCAACCTGTCAGATA-3′) and Gus (forward, 5′- CAAGAGCCAGT
TCCTCATCA-3′; reverse, 5′-TTGAAGTCCTTCACCAGCAG-3′). qPCRs were performed using the
SYBR® Select Master Mix (Thermo Fischer Scientific, Erembodegem, Belgium) in a QuantStudio 12K
Flex real-time PCR machine (Thermo Fischer Scientific, Erembodegem, Belgium). The cycling protocol
was as follows: 3 min at 50 ◦C and 3 min at 95 ◦C followed by 40 cycles of 3 s at 95 ◦C and 30 s at 61 ◦C.
Relative expression of the miRNAs and mRNA of interest were normalized against the three
reference genes using the qbase + qPCR analysis software (Biogazelle, Zwijnaarde, Belgium—www.
qbaseplus.com).
4.9. TLR4 Receptor Neutralization
dHL-60 cells (2 × 106 cells) were cultured in 12-well plates and pretreated with 1 µg/mL anti-TLR4
(R&D Systems, Minneapolis, MN, USA) or 1 µg/mL IgG isotypic control (Jackson ImmunoResearch,
Sufolk, UK) for 30 min. After pretreatment, dHL-60 cells were stimulated with 10 µg/mL S100A8/A9-P
for 18 h. 1 µg/mL anti-TLR4 or IgG isotypic control was added twice (every 6 h) during the stimulation.
4.10. Viral Transduction of miRNA Mimics in dHL-60
The most suitable promoter (mEF1αpromoter) for HL-60 cells was determined using SMARTchoice
Promoter Selection Plate from Dharmacon (Lafayette, CO, USA). The production of viruses was
performed using the Lenti-X Packaging Single Shots (VSV-G) transfection kit (Takara-Bio, Saint-Germain-
en-Laye, France) plus mEF1α promoter based lentiviral plasmids (Dharmacon, Lafayette, CO, USA)
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containing the expression sequence for miR-146a-5p or miR-155-5p or shRNA against GAPDH or a
non-targeting miRNA. Briefly, HEK 293T cells were seeded at 50,000 cells per cm2 in fibronectin-coated
Petri dishes. After 8 h, plasmids were added to the premixed viral plasmids/transfection reagent
and dispensed on HEK 293T cells. After 48 and 72 h, the virus-containing medium was collected,
pooled and concentrated by overlay on a sucrose-containing buffer (10% sucrose p/v, Tris-HCl 50 mM,
pH 7.4, NaCl 100 mM, EDTA 0.5 mM) at a 4:1 v/v ratio and centrifuged at 9500 g for 4 h at 4 ◦C.
Hank’s salt solution (Gibco) was added to the semi-dried pellet for re-suspension and placed overnight
in the dark at 4 ◦C [48]. The virus solution was tittered using the Lenti-X GoStix Plus (Takara-Bio,
Saint-Germain-en-Laye, France) according to the manufacturer’s recommendations. A concentration
of 107 to 109 IFU/mL was generally obtained and virus was directly used or stored at −80 ◦C in
107 IFU fraction.
For HL-60 infection, 0.1 × 106 cells per well were loaded in 24-well plates pre-coated overnight
with a solution of ACD-A (citrate dextrose form A) containing 20 µg/mL RetroNectin. 100 µL virus
(~107 IFU, MOI of 100) containing DEAE-dextran (6 µg/mL final concentration) was added to each
well, and then the plate was centrifuged at 300 g for 5 min and put back in the incubator at 37 ◦C and
5% CO2 for 6 h [49]. After this incubation time, the media was exchanged and the cells were left for
2 days in an incubator at 37 ◦C and 5% CO2 before starting the selection with 0.3 µg/mL puromycin for
21 days. To estimate transduction efficiency, GFP signals in the cells were visualized using microscopy
(Evos, Thermo Fischer Scientific, Erembodegem, Belgium).
4.11. Measurement of Cytokine Secretion by Cytometric Bead Array (CBA) and ELISA
1× 106 cells/mL transduced HL-60 cells were differentiated and stimulated for 6 h with S100A8/A9-P
(10 µg/mL). Fresh supernatants were immediately collected for subsequent quantitative measurements
of cytokine secretion using Cytometric Bead Array (CBA, BD Biosciences, Erembodegem, Belgium).
The multiplex standard curve composed of a mixture of 11 cytokine standards was determined using
serial dilutions, according to the manufacturer’s instructions. The mixture of selected capture beads
was prepared and added to supernatants for 1 h. The following beads were used: C-C motif chemokine
(CCL) 2 (MCP-1, bead D8), CCL3 (MIP-1α, bead B9), CCL5 (RANTES, bead D4), IL-1α (bead D6), IL-1β
(bead B4), IL-6 (bead A7), IL-8 (CXCL8, bead A9), IL-12b (bead E5), IFN-γ (bead E7), TNF-α (bead C4)
and TNFRII (bead C5). Then, a mixture of phycoerythrin detection reagents was added to each sample.
After 2 h of incubation, samples were carefully washed before flow cytometry acquisition on a BD
FACSCanto II system (BD Biosciences, Erembodegem, Belgium), adjusted using the calibration bead
procedure from the manufacturer. Results were quantified using standard curves and FCAP ArrayTM
software (Soft Flow, MinneapolisMN, USA).
CCL4 secretion was quantified by ELISA (R&D systems) according to the manufacturer’s
instructions. A LDH test was performed to check cell viability.
4.12. Statistical Analysis
The GraphPad Prism 7 software (GraphPad, La Jolla, CA, USA) was used to perform all statistical
analyses. For time course experiments based on multiple stimulatory conditions, a two-way ANOVA
analysis was first performed followed by a Tukey’s post-hoc test. For two-group comparison,
Student’s t-test was applied if normal distributions and equal variances were ascertained. Otherwise,
a Mann-Whitney test was done. A p-value below 5% was considered significant for all the statistical
tests and statistical significance was set as follows: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/22/
5699/s1.
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